EB-2 (NIW) for Polish Nationals

USCIS I-140 petition data for Poland nationals (FY2025 Q4 (Jul-Sep 2025)).

19 I-140 petitions 6 approved #34 by volume
Subcategory:

USCIS I-140 Data

Poland I-140 Petition Statistics

USCIS EB-2 (NIW) petition data for Poland nationals. FY2025 Q4 (Jul-Sep 2025).

I-140 Receipts

19

0.1% of all

I-140 Approvals

6

of 5,929 total

Volume Rank

#34

by I-140 receipts

Source: USCIS I-140 Performance Data, FY2025 Q4 (Jul-Sep 2025). Receipts and approvals for the reporting quarter.

Priority Date Tracker

Final Action Date

Oct 2024

ROW Final Action

Oct 2024

Source: DOS Visa Bulletin (2026-03)

Wait Time Estimator

Estimate Your Green Card Timeline

Enter your priority date and country to get a personalized estimate based on average DOS Final Action Date advancement over the last 12 months.

EB-2 (incl. NIW)

Sources: I-140/I-485 ranges from USCIS Processing Times, backlog advancement averaged over last 12 DOS Visa Bulletins. Estimates only.

Find Polish EB-2 (NIW) Cases

Browse real petition decisions and case studies from Poland, or join the waitlist to get notified when personalized case matching launches.

Country Comparison

USCIS I-140 data, FY2025 Q4 (Jul-Sep 2025)

CountryReceiptsApprovals
Grand Total 13,9832,968
China 2,330715
India 1,685426
Poland (current)196
Case Data Insights

We analyzed 4 publicly available EB-2 (NIW) petition decisions involving Poland nationals. Of these, 100% were approved or sustained. These cases span 2 industries and 2 job titles. Explore the charts below to see how decision outcomes have trended over time and which industries and roles have the highest success rates.

Decision Trends

0122022-012022-052022-092023-012023-052023-092024-012024-052024-092025-012025-05
Approved
Remanded
Denied

Top Industries

Biotechnology 3
Research and Development 1

Top Job Titles

Postdoctoral Researcher 1
Scientist 1

Policy Updates

General View all
Mar 2026 info Visa Bulletin

Visa Bulletin Update: EB-2 (2026-03)

The Department of State updated EB-2 Final Action Dates in the 2026-03 Visa Bulletin: - India: moved from 2013-07-15 to 2013-09-15 - Philippines: moved from 2024-04-01 to 2024-10-15 - Mexico: moved from 2024-04-01 to 2024-10-15 - Rest of World: moved from 2024-04-01 to 2024-10-15 This may allow additional applicants to proceed with their petitions.

advancementeb-2final-action-datepriority-date
Feb 2026 info Executive Order
Protecting the National Security and Welfare of the United States and its Citizens from Criminal Actors and Other Public Safety Threats

The policy directs DHS to maximize its use of criminal history record information (CHRI) for screening and vetting missions. This includes reciprocal data sharing with foreign governments, which will likely be utilized during the adjudication of EB-2 visas and National Interest Waivers.

vettingbackground checkssecurity screeningNIW
Jan 2026 warning USCIS Alert
USCIS to Increase Premium Processing Fees

The fee for Form I-907 is being adjusted upwards, impacting EB-2 petitioners who utilize expedited processing. This change is part of a broader USCIS effort to adjust fees for inflation and maintain service levels.

premium processinguscis feesNIWform i-907
Jan 2026 warning USCIS Memo
DHS Launches Landmark USCIS Fraud Investigation in Minnesota

The investigation focuses on identifying fraudulent activities within USCIS filings in the Minnesota region. EB-2 applicants may experience heightened vetting procedures, including more frequent Requests for Evidence (RFEs) and audits of employer credentials. This initiative is part of a broader DHS effort to ensure the integrity of employment-based immigration programs.

fraud investigationcomplianceUSCISDHS
Jan 2026 info Visa Bulletin

Visa Bulletin Update: EB-2 (2026-01)

The Department of State updated EB-2 Final Action Dates in the 2026-01 Visa Bulletin: - India: moved from 2013-05-15 to 2013-07-15 - China: moved from 2021-06-01 to 2021-09-01 - Philippines: moved from 2024-02-01 to 2024-04-01 - Mexico: moved from 2024-02-01 to 2024-04-01 - Rest of World: moved from 2024-02-01 to 2024-04-01 This may allow additional applicants to proceed with their petitions.

advancementeb-2final-action-datepriority-date

Frequently Asked Questions

At a Glance

USCIS Official Data

I-140 Receipts 19
I-140 Rank #34 of 191

Scraped Case Data

Decisions 4
Success Rate 100%
Country Share 0.1%
Approved / Sustained 4
Denied / Dismissed 0
Top Industry Biotechnology
Top Job Title Postdoctoral Researcher

Recent Decisions

View all

Others

Research and Development · Poland

WeGreened rfe approved
161 days 2025-05-01
The petitioner proposes to continue developing blood-based and digital biomarker diagnostics for complex mental illnesses such as schizophrenia and bipolar disorder. This work utilizes machine learning and cutting-edge analytics to probe immune system behavior for earlier diagnosis and treatment personalization.
View Case

Postdoctoral Researcher

Biotechnology · Poland

WeGreened approved
California 489 days 2025-04-22
The petitioner proposes to develop synthetic antibodies with enhanced functional activity against infectious agents, specifically focusing on antibody engineering strategies for conditions like HIV. This work aims to create potent, long-acting solutions for disease prevention and treatment to lower transmission rates and healthcare burdens.
View Case

Scientist

Biotechnology · Poland

WeGreened approved
North Carolina 12 days 2025-01-22
The petitioner proposes to continue research on engineering microorganisms for the biomanufacturing of valuable chemicals and pharmaceutical ingredients. This work focuses on establishing cost-effective domestic supply chains for essential compounds within the U.S. biotechnology sector.
View Case

Others

Biotechnology · Poland

WeGreened approved
Massachusetts 290 days 2022-01-10
The petitioner proposes to create novel in vivo models to study cancer development, elucidate protein functions, and uncover the roles of transcriptomic machinery. This work aims to increase the understanding of cell cycle proteins critical for cancer growth to improve cancer treatments and immunotherapies.
View Case